Ewing's sarcoma Clinical Trials EU — 11 Studies

Filter these 11 trials by phase, country, sponsor and more.

Open in Search →

Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very Hi … Pending

2024-518912-37-01 4 "Ewing Sarcoma"
Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas fol … Recruiting

2024-511337-35-00 4 2023-11-16 "The trial will include patients with so called "fusion-drive"
A trial to determine the dose, and evaluate the safety and pharmacokinetics of lutetium Lu 177 edotreotide in children with somatostatin rec … Recruiting

2024-512831-66-00 3 2025-10-24 "Pediatric participants aged two to less than 18 years old wi"
Long-term follow-up of patients treated with GD2IL18CART Recruiting

2025-521497-34-00 1 2025-10-06 "Neuroblastoma"
INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting

2024-511989-36-00 5 2025-09-24 "Ewing Sarcoma"
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting

2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 1 2024-04-12 "Neuroblastoma"
To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. Recruiting

2024-514441-11-00 4 2023-09-28
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting

2024-516078-31-00 10 2015-05-05 "Recurrent and Primary Refractory Ewing Sarcoma"
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL … Ended

2024-511975-14-00 9 2022-05-26 "recurrent/refractory Ewing sarcoma"
Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with ref … Ended

2024-513470-22-00 9 2019-03-22 "Progressive or refractory paediatric solid tumor"

Showing 1–11 of 11 trials